Physician profile
Claire E Hoverman
NPI 1851547384
$2,899.98
in general payments reported to CMS, 2019-2025
31 companies · $419 in 2025
The $419 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $285 · 2021: $522 · 2022: $398 · 2023: $573 · 2024: $384 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125 · Travel and Lodging: $167 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.66 |
| Travel and Lodging | $167.16 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $324.54 | 2019-2023 | Balcoltra |
| Abbvie INC. | $316.30 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $255.02 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $249.40 | 2019-2025 | Slynd |
| Hologic Sales and Service, LLC | $247.00 | 2019-2023 | Novasure, Myosure Tissue Removal Device, Omni Hysteroscope |
| Astellas Pharma US INC | $212.56 | 2019-2025 | Veozah, Myrbetriq |
| Intuitive Surgical, INC. | $167.16 | 2025 | |
| Mayne Pharma Commercial LLC | $99.64 | 2022 | |
| Organon LLC | $99.35 | 2021-2024 | |
| Daiichi Sankyo INC. | $83.46 | 2020-2024 | Injectafer |
| Agile Therapeutics, INC. | $82.32 | 2021-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $67.62 | 2020-2021 | |
| Roche Diagnostics Corporation | $64.52 | 2019-2020 | |
| Myriad Women'S Health, INC. | $60.45 | 2023 | Myrisk |
| Coopersurgical, INC. | $56.91 | 2019-2024 | Summit Doppler |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $50.78 | 2019-2020 | |
| Evofem Biosciences, INC. | $50.62 | 2022-2024 | |
| Novo Nordisk INC | $50.49 | 2023-2025 | Wegovy |
| Millicent US INC | $49.41 | 2019-2024 | Intrarosa |
| Merck Sharp & Dohme LLC | $49.15 | 2019-2020 | |
| Davol INC. | $41.53 | 2024-2025 | Arista, Arista Ah Flexitip |
| Biogen, INC. | $34.44 | 2025 | Zurzuvae |
| Lupin INC. | $29.06 | 2019 | |
| Exact Sciences Corporation | $27.48 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $25.20 | 2021 | |
| Therapeuticsmd, INC. | $24.87 | 2019 | |
| Meditrina | $22.99 | 2023 | |
| Axonics, INC. | $17.13 | 2024 | Bulkamid |
| Duchesnay USA Incorporated | $14.91 | 2019 | |
| Aspira Women'S Health INC | $13.96 | 2024 | Ova1 |
| Allergan, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Hoverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.